-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexaria wins ethics board clearance for oral semaglutide human pilot study #7

PUBT·05/19/2026 13:15:28
Listen to the news
Lexaria wins ethics board clearance for oral semaglutide human pilot study #7
  • Lexaria Bioscience received independent review board ethics clearance to launch Human Pilot Study #7 testing two oral DehydraTECH-semaglutide formulations against Novo Nordisk’s Wegovy tablets.
  • The five-week, three-arm study will assess safety, tolerability, and pharmacokinetics under fasted dosing conditions, with dosing expected to start in mid-June.
  • Results are aimed at supporting potential commercial partnerships tied to Lexaria’s oral GLP-1 delivery technology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605190915ACCESSWRNAPR_____1167517) on May 19, 2026, and is solely responsible for the information contained therein.